Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer

This study is testing furmonertinib, a targeted drug for lung cancer with specific gene mutations, as a follow-up treatment (adjuvant therapy) after surgery in people with early-stage non-small cell lung cancer (NSCLC) that has specific high-risk features. **You may be eligible if...** - You have had surgery to remove your lung cancer - You have been diagnosed with non-small cell lung cancer (confirmed by two pathologists) - Your cancer is stage IA with high-risk features OR stage IB - Your cancer has a specific EGFR gene mutation confirmed by genetic testing - Your overall health is good **You may NOT be eligible if...** - You received any cancer treatment before surgery - Your cancer does not have an EGFR mutation - You have significant organ dysfunction or immune conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.